Status
Conditions
Treatments
About
The goal of this proposed clinical case series is to evaluate the effect of a non-invasive vagus nerve stimulation paradigm on: 1) Symptom reporting via validated patient reported outcomes, and 2) objective clinical biomarkers of autonomic nervous system function.
This will be a placebo controlled, randomized controlled trial with a crossover design built in. This study will aim to recruit 40 people with Long COVID to be a part of this research.
Full description
Participants will be randomized into one of two arms. Those in the "active VNS" arm will be sent home with a portable VNS device and asked to perform a daily VNS protocol designed to down regulate sympathetic nervous system activity for six weeks.
Those in the "sham VNS" arm will be asked to use the VNS device daily on a sham setting for six weeks. Those randomized to the sham group will be given the opportunity to "crossover" into the active VNS arm once they have completed the sham arm (Week 12). The participant and assessor will be blinded.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
At least 18 years of age
Clinical diagnosis of dysautonomia following an acute COVID-19 infection at least 3 months prior. See below for criteria:
2 or more if the following clinical assessment findings
symptomatic exacerbation during active stand test
tachycardia on active stand test
tachycardia on orthostatic vitals assessment
hypotension on orthostatic vitals assessment
hypertension in orthostatic vitals assessment
symptom exacerbation on orthostatic vitals assessment
English speaking
Exclusion criteria
• Pregnancy or lactation:
Pregnant persons will not be included in this study for the following reasons:
According to the device manufacturer, the following contraindications will be followed during the screening process:
Primary purpose
Allocation
Interventional model
Masking
40 participants in 2 patient groups
Loading...
Central trial contact
Mackenzie Doerstling, MPH
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal